ClinicalTrials.gg
CompletedNCT01899053Updated Oct 30, 2019Results posted

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

A Phase 1 interventional study of TAK-228 and TAK-117 in Advanced Nonhematologic Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-30.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
101
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to evaluate the safety and to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and dosing schedules of oral TAK-228+TAK-117. It also evaluated the single- and multiple-dose plasma pharmacokinetics (PK) of TAK-228+TAK-117 in participants with advanced nonhematologic malignancies.

Read the detailed description

The drug being tested in this study was TAK-228. TAK-228 was tested to evaluate the safety, pharmacokinetics and efficacy, of TAK-228 in combination with TAK-117 when administered to adult participants with advanced nonhematologic malignancies.

The study enrolled 101 patients. The study consisted of 2 phases: an escalation stage followed by an expansion stage. Participants in escalation stage were assigned to the following treatment arms:

  • Dose escalation treatment arm A: TAK-228 2 or 4 mg capsule
  • Dose escalation treatment arm B: TAK-228 3, 4, 6 or 8 mg capsule
  • Dose escalation treatment arm C: TAK-228 3 mg capsule

Upon completion of the escalation stage, 1 combination treatment regimen was selected for further safety, tolerability, pharmacokinetics, and mutual drug-drug interaction characterization in the expansion stage. During treatment, participants in both stages received TAK-228 and TAK-117 capsules at prespecified doses in repeated 28-day cycles.

This multi-center trial conducted in the United States, United Kingdom and Spain. The overall time to participate in this study was approximately 68 weeks. Participants made multiple visits to the clinic, and a final visit after 30 days after last dose of study drug.

02

Conditions studied

  • Advanced Nonhematologic Malignancies

Keywords

  • Drug Therapy
  • TAK-228
  • TAK-117
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants 18 years or older
  • Participants must have a diagnosis and documented disease progression of a solid tumor , excluding primary brain tumor, for which standard, curative, or life prolonging treatment does not exist or is no longer effective
  • (ECOG) performance status 0-1
  • Female participants who are for at least 1 year prior to screening. For women of agree to practice 2 effective methods of or agree to practice true abstinence
  • Male participants must agree to practice effective barrier contraception during the entire study treatment period and through 30 days after last dose of study drug or practice true abstinence
  • Voluntary written consent
  • Suitable venous access
  • Participants must have a block of banked tumor tissue and/or fresh tumor tissue or at least 10 unstained slides available to be sent to the central laboratory
  • Clinical laboratory values as specified in the protocol
  • Participants must have radiographically or clinically evaluable tumor

Exclusion criteria

Exclusion Criteria:

  • Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment
  • Treatment with any products within 30 days before the first dose of study drug
  • Previous treatment with TAK-117 and/or TAK-228; previous treatment with dual mTORC1/2 or dual PI3K-mTOR inhibitors
  • Failed to have recovered from the reversible effects of previous anticancer therapies
  • Have received systemic (inhalers are allowed) within 7 days before the first administration of study drug
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drug
  • Diagnosis of diabetes mellitus
  • Other co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active infection
  • Known (HIV) infection
  • Cardiovascular conditions as defined in the protocol
  • A requirement for positive inotropic support (excluding digoxin) or serious uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation) within 1 year before screening
  • Participants who are taking proton pump inhibitors within 7 days of the first dose or who require treatment with proton pump inhibitors during the trial or those who are taking histamine-2 (H2) receptor antagonists within 24 hours of the first dose
  • Participants who received previous therapy with PI3K inhibitors or rapalogs will be allowed in the study if all other inclusion/exclusion criteria are met
  • Diagnosis of primary brain tumor or symptomatic . Participants with brain metastases must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Dose Escalation Treatment Arm A

    TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.

    Drug: TAK-228 · Drug: TAK-117

  • Experimental
    Dose Escalation Treatment Arm B

    TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.

    Drug: TAK-228 · Drug: TAK-117

  • Experimental
    Dose Escalation Treatment Arm C

    TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.

    Drug: TAK-228 · Drug: TAK-117

  • Experimental
    Drug-Drug Interaction (DDI) Expansion Cohort

    TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.

    Drug: TAK-228 · Drug: TAK-117

Interventions

  • TAK-228 Capsules

    Also known as: MLN0128, INK128 or Sapanisertib

  • TAK-117 Capsules

    Also known as: MLN1117

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above-mentioned criteria.

    Time frame: From Baseline to 30 days after the last dose of study drug (Up to approximately 68 weeks)

  2. Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  3. Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  4. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  5. Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  6. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  7. RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort

    Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) \[Cycle 1 Day 24\]/ AUC(0-24) \[Cycle1 Day 1\].

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  8. Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  9. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  10. Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  11. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  12. Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  13. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  14. RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort

    Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) \[Cycle 1 Day 24\]/ AUC(0-24) \[Cycle1 Day 1\].

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  15. Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort

    Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose

  16. Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose

  17. Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose

  18. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose

  19. Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose

  20. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose

  21. Peak to Trough Ratio for TAK-228 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose

  22. Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose

  23. Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose

  24. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose

  25. Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose

  26. CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose

  27. Peak to Trough Ratio for TAK-117 in DDI Expansion Cohort

    Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose

Secondary outcomes

  1. Objective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.

    Time frame: Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)

  2. Duration of Response (DOR)

    The DOR is defined as the time from the date of first documented response of CR/PR to the first documented progressive disease (PD), or censored at the last response assessment date that is SD or better for a participant that has not progressed. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.

    Time frame: Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)

07

Results

Posted Oct 30, 2019

Participant flow

Participants took part in the study at 5 investigative sites in Spain, United Kingdom and United States from 28 June 2013 to 30 April 2018.

Participant flow — Overall Study
MilestoneDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)
Started73736333631671420
Completed00000000000000
Not completed73736333631671420
Withdrew: Progressive disease4030311143125817
Withdrew: Adverse event11131110203122
Withdrew: Reason not specified00000010000010
Withdrew: Withdrawal by subject11202001000011
Withdrew: Protocol violation00100000000000
Withdrew: Unsatisfactory therapeutic response11000000001000
Withdrew: Symptomatic deterioration00000101000120

Outcome measures

PrimaryNumber of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above-mentioned criteria.

Time frame:
From Baseline to 30 days after the last dose of study drug (Up to approximately 68 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)
AEs73735333631671419
SAEs20111011114469
PrimaryTmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Median · hour
Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
hourDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 11.000 (0.50 to 4.00)1.000 (0.97 to 1.03)1.000 (0.50 to 4.07)2.050 (0.53 to 2.07)1.033 (1.00 to 2.08)2.083 (1.97 to 4.02)1.000 (0.48 to 1.07)1.067 (1.03 to 8.12)1.358 (0.50 to 4.00)1.067 (0.98 to 3.83)1.000 (0.50 to 2.15)0.725 (0.43 to 2.08)0.983 (0.47 to 4.17)
Cycle 1, Day 241.000 (0.50 to 2.00)0.758 (0.48 to 1.03)1.400 (0.45 to 4.08)—2.000 (0.92 to 2.25)4.000 (1.00 to 4.12)1.408 (1.00 to 1.82)0.617 (0.48 to 2.00)0.925 (0.50 to 2.15)4.000 (4.000 to 4.000)1.033 (0.47 to 2.30)2.083 (1.95 to 4.87)1.017 (0.50 to 7.03)
PrimaryCmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
ng/mLDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 124.63 ± 7.35539.73 ± 7.85325.80 ± 8.18828.67 ± 3.70218.26 ± 8.61021.69 ± 29.27348.90 ± 28.15733.30 ± 16.30153.10 ± 7.25753.53 ± 29.78842.17 ± 11.49527.53 ± 11.66526.51 ± 12.788
Cycle 1, Day 2427.78 ± 6.63253.55 ± 2.19229.45 ± 9.746—13.75 ± 6.93837.36 ± 49.07846.10 ± 17.25372.43 ± 13.09461.58 ± 14.89417.1 ± 050.68 ± 12.05517.75 ± 4.86535.59 ± 18.415
PrimaryAUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ng*hr/mL
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
ng*hr/mLDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 1120.888 ± 36.1184247.361 ± 156.0211138.929 ± 37.3727230.983 ± 14.6292109.622 ± 45.6613126.062 ± 120.8204303.897 ± 152.5659287.283 ± 268.7088351.602 ± 122.6407382.588 ± 250.2623249.341 ± 128.4868168.408 ± 103.9245160.670 ± 90.6815
Cycle 1, Day 24206.418 ± 169.5373208.389 ± 78.6461200.762 ± 56.1368—115.884 ± 50.7913203.836 ± 120.1336410.604 ± 265.8768535.365 ± 256.8762331.286 ± 133.7879305.97 ± 0317.111 ± 151.6045132.058 ± 71.7154211.792 ± 100.9091
PrimaryTerminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · hour
Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
hourDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 15.090 ± 2.16535.783 ± 3.39416.214 ± 2.66497.450 ± 0.73686.975 ± 1.01084.65 ± 08.412 ± 1.39964.96 ± 05.792 ± 3.44056.799 ± 5.57406.320 ± 1.78395.512 ± 2.15987.593 ± 1.1365
Cycle 1, Day 245.489 ± 2.47824.686 ± 2.12655.521 ± 1.6417—7.635 ± 1.12535.43 ± 08.5 ± 06.808 ± 1.73266.221 ± 1.0591—5.940 ± 1.67376.42 ± 06.354 ± 1.9320
PrimaryCL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · L/hour
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
L/hourDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 116.534 ± 5.476219.049 ± 11.855814.419 ± 7.56367.694 ± 0.575015.311 ± 3.676211.38 ± 010.728 ± 6.966928.54 ± 019.999 ± 10.050916.259 ± 9.372517.924 ± 9.526122.715 ± 14.725213.933 ± 5.4880
Cycle 1, Day 2414.720 ± 4.582418.207 ± 4.181910.597 ± 3.9917—15.683 ± 2.91499.23 ± 013.58 ± 012.817 ± 4.792919.060 ± 7.1913—14.196 ± 5.313715.53 ± 016.133 ± 8.6701
PrimaryRAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort

Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) \[Cycle 1 Day 24\]/ AUC(0-24) \[Cycle1 Day 1\].

Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ratio
RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort
ratioDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort2.225 ± 1.45761.25 ± 01.495 ± 0.1884—1.219 ± 0.34971.569 ± 0.40991.712 ± 0.26501.718 ± 0.43291.015 ± 0.14531.58 ± 01.172 ± 0.33631.213 ± 0.13061.461 ± 0.2246
PrimaryPeak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ratio
Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
ratioDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 116.546 ± 6.565913.588 ± 8.364914.553 ± 6.880710.420 ± 1.566213.983 ± 6.678223.757 ± 31.152514.336 ± 7.098620.212 ± 22.035713.227 ± 8.38345.761 ± 1.525022.676 ± 14.214215.012 ± 6.525310.725 ± 2.7876
Cycle 1, Day 2412.145 ± 6.046527.66 ± 014.691 ± 8.1076—9.363 ± 6.633621.864 ± 33.15419.305 ± 4.796921.979 ± 13.791131.971 ± 19.64101.8 ± 022.555 ± 10.40068.805 ± 7.380521.157 ± 14.9668
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Median · hour
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort
hourDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 10.800 (0.50 to 2.03)2.000 (1.03 to 2.00)2.050 (0.52 to 4.08)2.050 (1.03 to 2.07)3.017 (1.85 to 7.50)1.97 (1.97 to 1.97)2.000 (1.07 to 4.18)1.033 (0.50 to 8.12)4.008 (0.50 to 7.25)3.883 (2.42 to 7.33)1.925 (1.00 to 4.15)2.083 (0.95 to 6.03)3.125 (0.50 to 22.58)
Cycle 1, Day 241.000 (0.55 to 4.00)1.025 (1.02 to 1.03)4.108 (0.93 to 8.02)—2.417 (1.97 to 4.00)2.000 (1.92 to 4.00)1.408 (1.00 to 1.82)0.883 (0.62 to 4.05)3.150 (2.00 to 7.02)7.33 (7.33 to 7.33)2.000 (1.00 to 8.02)2.050 (1.40 to 4.27)1.117 (0.95 to 8.07)
PrimaryCmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort
ng/mLDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 11800.0 ± 1049.25988.7 ± 858.573067.1 ± 1243.504950.0 ± 3381.064136.7 ± 1487.682420 ± 03836.7 ± 656.071631.3 ± 1305.252711.7 ± 1172.972568.7 ± 2107.043369.4 ± 1417.313077.7 ± 1629.053353.0 ± 1955.02
Cycle 1, Day 242514.0 ± 1597.132720.0 ± 1286.933438.3 ± 1687.00—3624.0 ± 2925.791054.8 ± 1454.946180.0 ± 127.284876.7 ± 848.844477.5 ± 953.88100 ± 04863.3 ± 1142.543755.0 ± 2831.784805.3 ± 2893.99
PrimaryAUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ng*hr/mL
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
ng*hr/mLDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 114586.139 ± 10434.544511550.908 ± 11672.085243948.190 ± 25421.342869617.994 ± 46233.089854993.211 ± 27446.451726746.78 ± 047803.262 ± 4758.741823148.610 ± 27836.887838563.109 ± 23484.807739903.517 ± 33243.121238224.835 ± 22368.016330925.255 ± 15126.491346451.606 ± 33137.8861
Cycle 1, Day 2431723.844 ± 38363.487222566.251 ± 13562.890050960.181 ± 32295.5320—46278.615 ± 48171.798212428.783 ± 16745.786190462.795 ± 14090.467667186.097 ± 49493.058455908.919 ± 39888.96991674.23 ± 072432.560 ± 27615.680246164.679 ± 37938.020870490.572 ± 58515.7794
PrimaryTerminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · hour
Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
hourDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 16.590 ± 3.46734.92 ± 0—————3.839 ± 3.54987.465 ± 2.2023—4.858 ± 2.79286.379 ± 1.53697.368 ± 0.3774
Cycle 1, Day 245.722 ± 3.12596.53 ± 02.98 ± 0—3.2 ± 08.37 ± 0—6.233 ± 4.48134.61 ± 0—7.717 ± 2.64285.853 ± 2.15345.984 ± 3.6558
PrimaryCL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · L/hr
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
L/hrDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 116.993 ± 23.64969.79 ± 0—————194.998 ± 258.275120.944 ± 16.6625—17.879 ± 17.807221.075 ± 16.411632.455 ± 35.8687
Cycle 1, Day 2413.821 ± 16.50477.18 ± 017.95 ± 0—9.25 ± 019.7 ± 0—5.328 ± 1.27945.45 ± 0—4.803 ± 2.759911.199 ± 8.433467.750 ± 110.0873
PrimaryRAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort

Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) \[Cycle 1 Day 24\]/ AUC(0-24) \[Cycle1 Day 1\].

Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ratio
RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort
ratioDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort0.965 ± 0.14231.33 ± 01.161 ± 0.2506—1.049 ± 0.90331.18 ± 02.007 ± 0.47662.687 ± 0.57001.748 ± 1.15750.91 ± 01.879 ± 1.57720.925 ± 0.62814.183 ± 5.8060
PrimaryPeak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
Time frame:
Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ratio
Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
ratioDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)
Cycle 1, Day 120.138 ± 21.60138.845 ± 7.85162.551 ± 0.96732.676 ± 0.16354.373 ± 3.32853.93 ± 03.602 ± 0.83616.640 ± 7.37466.877 ± 8.86002.631 ± 0.59936.872 ± 8.368011.494 ± 10.94303.426 ± 2.3804
Cycle 1, Day 2410.023 ± 9.043511.256 ± 7.14262.294 ± 0.5975—20.124 ± 33.89913.931 ± 2.43693.464 ± 0.139954.242 ± 87.144511.832 ± 15.47661.96 ± 05.482 ± 6.707511.184 ± 8.08694.664 ± 3.9973
PrimaryTmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Median · hour
Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort
hourDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 3, TAK-228 administered alone1.000 (0.38 to 4.08)
Cycle 1, Day 10, TAK-228 administered with TAK-1170.983 (0.42 to 2.02)
PrimaryCmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort
ng/mLDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 3, TAK-228 administered alone60.02 ± 21.808
Cycle 1, Day 10, TAK-228 administered with TAK-11771.99 ± 22.546
PrimaryAUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ng*hr/mL
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion Cohort
ng*hr/mLDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 3, TAK-228 administered alone301.613 ± 123.9584
Cycle 1, Day 10, TAK-228 administered with TAK-117390.307 ± 155.3378
PrimaryTerminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · hour
Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion Cohort
hourDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 3, TAK-228 administered alone6.823 ± 2.1608
Cycle 1, Day 10, TAK-228 administered with TAK-1176.546 ± 1.8351
PrimaryCL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · L/hour
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion Cohort
L/hourDrug-Drug Interaction (DDI) Expansion Cohort (Milled))
Cycle 1, Day 3, TAK-228 administered alone15.368 ± 10.9714
Cycle 1, Day 10, TAK-228 administered with TAK-11713.359 ± 11.3718
PrimaryPeak to Trough Ratio for TAK-228 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ratio
Peak to Trough Ratio for TAK-228 in DDI Expansion Cohort
ratioDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 3, TAK-228 administered alone22.982 ± 11.6286
Cycle 1, Day 10, TAK-228 administered with TAK-11723.931 ± 15.6395
PrimaryTmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Median · hour
Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort
hourDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 10, TAK-117 administered with TAK-2281.033 (0.50 to 4.12)
Cycle 1, Day 17, TAK-117 administered alone1.983 (0.50 to 7.25)
PrimaryCmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort
ng/mLDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 10, TAK-117 administered with TAK-2285357.3 ± 2842.40
Cycle 1, Day 17, TAK-117 administered alone5332.6 ± 2955.51
PrimaryAUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ng*hr/mL
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion Cohort
ng*hr/mLDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 10, TAK-117 administered with TAK-22861148.949 ± 42799.7918
Cycle 1, Day 17, TAK-117 administered alone63975.156 ± 53764.5716
PrimaryTerminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · hour
Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion Cohort
hourDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 10, TAK-117 administered with TAK-2286.420 ± 2.3635
Cycle 1, Day 17, TAK-117 administered alone5.717 ± 2.3715
PrimaryCL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · L/hour
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion Cohort
L/hourDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 10, TAK-117 administered with TAK-22811.797 ± 18.0040
Cycle 1, Day 17, TAK-117 administered alone9.134 ± 8.7741
PrimaryPeak to Trough Ratio for TAK-117 in DDI Expansion Cohort
Time frame:
Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Reported as:
Mean · ratio
Peak to Trough Ratio for TAK-117 in DDI Expansion Cohort
ratioDrug-Drug Interaction (DDI) Expansion Cohort (Milled)
Cycle 1, Day 10, TAK-117 administered with TAK-2287.423 ± 7.423
Cycle 1, Day 17, TAK-117 administered alone21.357 ± 44.3461
SecondaryObjective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

ORR defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.

Time frame:
Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
percentage of participantsDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)
Objective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.10.00.00.00.00.00.00.00.00.00.00.00.00.020.0
SecondaryDuration of Response (DOR)

The DOR is defined as the time from the date of first documented response of CR/PR to the first documented progressive disease (PD), or censored at the last response assessment date that is SD or better for a participant that has not progressed. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.

Time frame:
Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)
Reported as:
Median · days
Duration of Response (DOR)
daysDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)
Duration of Response (DOR)—————————————92 (1 to 288)

Adverse events

Collected over Baseline up to 30 days after the last dose of study drug (Up to approximately 68 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation Treatment Arm A: Cohort 1A0/7 (0%)2/7 (28.6%)6/7 (85.7%)
Dose Escalation Treatment Arm A: Cohort 2A0/3 (0%)0/3 (0%)3/3 (100%)
Dose Escalation Treatment Arm A: Cohort 3A1/7 (14.3%)1/7 (14.3%)7/7 (100%)
Dose Escalation Treatment Arm A: Cohort 3A (Milled)0/3 (0%)1/3 (33.3%)3/3 (100%)
Dose Escalation Treatment Arm A: Cohort 4A1/6 (16.7%)1/6 (16.7%)5/6 (83.3%)
Dose Escalation Treatment Arm B: Cohort 1B0/3 (0%)0/3 (0%)3/3 (100%)
Dose Escalation Treatment Arm B: Cohort 2B0/3 (0%)1/3 (33.3%)3/3 (100%)
Dose Escalation Treatment Arm B: Cohort 3B0/3 (0%)1/3 (33.3%)3/3 (100%)
Dose Escalation Treatment Arm B: Cohort 3B (Milled)0/6 (0%)1/6 (16.7%)6/6 (100%)
Dose Escalation Treatment Arm B: Cohort 4B0/3 (0%)1/3 (33.3%)3/3 (100%)
Dose Escalation Treatment Arm B: Cohort 5B (Milled)2/16 (12.5%)4/16 (25%)16/16 (100%)
Dose Escalation Treatment Arm C: Cohort 1C0/7 (0%)4/7 (57.1%)7/7 (100%)
Dose Escalation Treatment Arm C: Cohort 2C (Milled)0/14 (0%)6/14 (42.9%)13/14 (92.9%)
Drug-Drug Interaction (DDI) Expansion Cohort (Milled)2/20 (10%)9/20 (45%)19/20 (95%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)
GastritisGastrointestinal disorders0/70/30/70/30/60/31/30/30/60/30/160/70/140/20
HyperkalaemiaMetabolism and nutrition disorders0/70/30/70/30/60/31/30/30/60/30/160/70/140/20
Tumour fistulisationNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/70/30/70/30/60/30/30/30/61/30/160/70/140/20
Ischaemic strokeNervous system disorders0/70/30/71/30/60/30/30/30/60/30/160/70/140/20
Nerve compressionNervous system disorders0/70/30/70/30/60/30/31/30/60/30/160/70/140/20
Intestinal perforationGastrointestinal disorders0/70/30/70/31/60/30/30/30/60/30/160/70/140/20
Upper gastrointestinal haemorrhageGastrointestinal disorders0/70/30/70/30/60/30/30/31/60/30/160/70/140/20
Bile duct obstructionHepatobiliary disorders0/70/30/70/30/60/30/30/31/60/30/160/70/140/20
Neutrophil count decreasedInvestigations0/70/30/70/30/60/30/30/31/60/30/160/70/140/20
EnterocolitisGastrointestinal disorders1/70/30/70/30/60/30/30/30/60/30/160/70/140/20
Most frequent other events
Showing 10 of 219
Most frequent other events
EventDose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)
NauseaGastrointestinal disorders3/72/36/73/34/61/33/33/35/63/311/164/710/1411/20
VomitingGastrointestinal disorders1/71/35/72/33/60/32/32/34/63/38/162/79/149/20
FatigueGeneral disorders3/73/33/71/33/63/32/31/32/62/36/162/76/144/20
DiarrhoeaGastrointestinal disorders3/72/33/71/32/62/32/31/32/62/36/163/77/146/20
StomatitisGastrointestinal disorders1/72/32/72/32/62/30/31/31/61/30/160/73/147/20
ConstipationGastrointestinal disorders1/72/33/70/32/60/30/31/32/60/33/163/73/143/20
Oral painGastrointestinal disorders1/72/31/70/30/60/31/30/30/60/31/160/70/140/20
PainGeneral disorders0/70/30/70/30/62/30/30/30/60/30/160/70/140/20
Aspartate aminotransferase increasedInvestigations1/72/33/71/33/62/30/31/33/61/31/161/73/142/20
Alanine aminotransferase increasedInvestigations1/71/32/71/33/62/30/31/33/61/31/161/72/142/20

Baseline characteristics

Safety population consisted of all enrolled participants who received at least 1 dose of any study drug.

Age, Continuous
Age, Continuous(years)Dose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)Total
Mean59.9 ± 6.3169.3 ± 5.1350.6 ± 14.0566.7 ± 5.8648.7 ± 11.6674.3 ± 5.1369.3 ± 14.1568.3 ± 9.2458.0 ± 7.7268.3 ± 4.1656.6 ± 9.6953.3 ± 14.3656.5 ± 6.9763.4 ± 9.1059.4 ± 10.96
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)Total
Female727321214211271364
Male0100421221557737
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)Total
Hispanic or Latino000010001010148
Not Hispanic or Latino727353325213713981
Unknown or Not Reported0100000101200712
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)Total
White7273533343134141990
Black Or African American010000000013005
Asian000010001000002
Not Reported000000001010013
Other000000000010001
Region of Enrollment
Region of Enrollment(Participants)Dose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)Total
United Kingdom0000000211312111
Spain00103010315141231
United States7363332121858759
Height
Height(cm)Dose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)Total
Mean164.0 ± 3.84165.1 ± 5.08161.6 ± 3.26159.4 ± 7.73169.8 ± 8.73169.0 ± 12.86157.3 ± 4.25168.5 ± 15.02168.3 ± 12.41168.5 ± 8.30168.7 ± 11.24180.7 ± 9.35170.7 ± 7.86163.7 ± 7.64167.3 ± 9.67
Weight
Weight(kg)Dose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)Total
Mean63.8 ± 9.1178.4 ± 1.3469.7 ± 14.2049.8 ± 8.0679.5 ± 19.9167.6 ± 20.3362.5 ± 15.3273.7 ± 17.3278.2 ± 22.6579.3 ± 9.1171.4 ± 13.0079.9 ± 15.1978.6 ± 17.5564.6 ± 12.0871.4 ± 15.63
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Dose Escalation Treatment Arm A: Cohort 1ADose Escalation Treatment Arm A: Cohort 2ADose Escalation Treatment Arm A: Cohort 3ADose Escalation Treatment Arm A: Cohort 3A (Milled)Dose Escalation Treatment Arm A: Cohort 4ADose Escalation Treatment Arm B: Cohort 1BDose Escalation Treatment Arm B: Cohort 2BDose Escalation Treatment Arm B: Cohort 3BDose Escalation Treatment Arm B: Cohort 3B (Milled)Dose Escalation Treatment Arm B: Cohort 4BDose Escalation Treatment Arm B: Cohort 5B (Milled)Dose Escalation Treatment Arm C: Cohort 1CDose Escalation Treatment Arm C: Cohort 2C (Milled)Drug-Drug Interaction (DDI) Expansion Cohort (Milled)Total
Mean23.7 ± 2.8028.8 ± 2.0926.7 ± 5.6519.9 ± 5.0627.3 ± 5.0923.2 ± 3.3625.4 ± 7.1826.2 ± 6.7627.2 ± 4.6027.9 ± 3.1125.2 ± 4.3024.3 ± 3.2727.0 ± 5.7424.1 ± 4.0625.4 ± 4.66
08

Study locations

5 sites
  • Boston, Massachusetts, United States
  • Nashville, Tennessee, United States
  • San Antonio, Texas, United States
  • Barcelona, Spain
  • Sutton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2013 to primary completion in Jan 2017, 43 months.

Results were first posted in Oct 2019, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2013
First posted
Jul 15, 2013
StartActual
Jun 28, 2013
Primary completionActual
Jan 31, 2017
CompletionActual
Apr 30, 2018
Results first posted
Oct 30, 2019
Last update
Oct 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01899053
Responsible party
Sponsor
First posted
Jul 15, 2013
Start date
Jun 28, 2013
Primary completion
Jan 31, 2017
Completion
Apr 30, 2018
Results posted
Oct 30, 2019
Last update
Oct 30, 2019

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sapanisertib · Serabelisib

Start the discussion